Abstract:N6-methyladenosine (m6A) is the most abundant epigenetic modification of RNA, and its dysregulation drives aberrant transcription and translation programs that promote cancer occurrence and progression. Although defective gene regulation resulting from m6A often affects oncogenic and tumor-suppressing networks, m6A can also modulate tumor immunogenicity and immune cells involved in anti-tumor responses. Understanding this counterintuitive concept can aid the design of new drugs that target m6A to potentially improve the outcomes of cancer immunotherapies. Here, we provide an up-to-date and comprehensive overview of how m6A modifications intrinsically affect immune cells and how alterations in tumor cell m6A modifications extrinsically affect immune cell responses in the tumor microenvironment (TME). We also review strategies for modulating endogenous anti-tumor immunity and discuss the challenge of reshaping the TME. Strategies include: combining specific and efficient inhibitors against m6A regulators with immune checkpoint blockers; generating an effective programmable m6A gene-editing system that enables efficient manipulation of individual m6A sites; establishing an effective m6A modification system to enhance anti-tumor immune responses in T cells or natural killer cells; and using nanoparticles that specifically target tumor-associated macrophages (TAMs) to deliver messenger RNA or small interfering RNA of m6A-related molecules that repolarize TAMs, enabling them to remodel the TME. The goal of this review is to help the field understand how m6A modifications intrinsically and extrinsically shape immune responses in the TME so that better cancer immunotherapy can be designed and developed.

Dual Effects of N6-methyladenosine on Cancer Progression and Immunotherapy

The emerging roles of N6-methyladenosine RNA methylation in human cancers

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N6-Methyladenosine in Cancer Immunotherapy: an Undervalued Therapeutic Target

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

Role of N6-methyladenosine RNA modification in cancer

N6-methyladenosine (m6a) RNA Modification in Tumor Immunity

N6-methyladenosine-dependent Signalling in Cancer Progression and Insights into Cancer Therapies

Targeting the RNA M6a Modification for Cancer Immunotherapy

The Implications of N6-methyladenosine (m6a) Modification in Esophageal Carcinoma

Functions of N6-methyladenosine and Its Role in Cancer

Mechanisms of N6‑methyladenosine Modification in Tumor Development and Potential Therapeutic Strategies (Review)

N6-methyladenosine links RNA metabolism to cancer progression

Emerging Regulatory Mechanisms of N6-Methyladenosine Modification in Cancer Metastasis

Dynamic M6a-Ncrnas Association and Their Impact on Cancer Pathogenesis, Immune Regulation and Therapeutic Response

N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy

N6-methyladenosine modification: a novel pharmacological target for anti-cancer drug development

The Importance of N6-methyladenosine Modification in Tumor Immunity and Immunotherapy.

Link Between M6a Modification and Cancers

N6-methyladenosine (m6a) As a Regulator of Carcinogenesis and Drug Resistance by Targeting Epithelial-Mesenchymal Transition and Cancer Stem Cells